Ionis Pharmaceuticals Inc (NAS:IONS)
$ 39.21 0.94 (2.46%) Market Cap: 5.72 Bil Enterprise Value: 4.82 Bil PE Ratio: 0 PB Ratio: 19.32 GF Score: 66/100

Ionis Pharmaceuticals Inc at BMO Capital Markets Prescription for Success Healthcare Conference (Virtual) Transcript

Jun 23, 2020 / 06:00PM GMT
Release Date Price: $57.82 (-2.56%)
Guyn Kim
BMO Capital Markets Equity Research - Analyst

Good afternoon. My name is Do Kim. I'm one of the biotech analysts at BMO. For our next fireside chat, we have with us Eric Swayze, SVP of Research at Ionis Pharmaceuticals; and Wade Walke, Head of Investor Relations.

Questions & Answers

Guyn Kim
BMO Capital Markets Equity Research - Analyst

Could you start by providing us a brief update of the commercial products and the typical goals for this year for the late case trials and the proof-of-concept studies you're running?

D. Wade Walke
Ionis Pharmaceuticals, Inc. - VP of IR

You bet. I'll kick it off. This is a Wade Walke. It's a very exciting time for us at Ionis. We have a lot of things going on, as we usually do. We have -- but this year's -- it's kind of a special year. We have a new CEO, Brett Monia, who has a vision to build off the tremendous achievements of the last 30 years and take the company really to the next level, with the vision of Ionis as really the leader in biotech and a company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot